Polydex Pharmaceuticals Stock Price To Sales
POLXFDelisted Stock | USD 1.96 0.01 0.51% |
Polydex Pharmaceuticals fundamentals help investors to digest information that contributes to Polydex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Polydex Pink Sheet. The fundamental analysis module provides a way to measure Polydex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Polydex Pharmaceuticals pink sheet.
Polydex |
Polydex Pharmaceuticals Company Price To Sales Analysis
Polydex Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Polydex Pharmaceuticals Price To Sales | 0.51 X |
Most of Polydex Pharmaceuticals' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Polydex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Polydex Pharmaceuticals has a Price To Sales of 0.5061 times. This is 97.64% lower than that of the Pharmaceuticals sector and 99.49% lower than that of the Health Care industry. The price to sales for all United States stocks is 95.57% higher than that of the company.
Polydex Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Polydex Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Polydex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Polydex Pharmaceuticals by comparing valuation metrics of similar companies.Polydex Pharmaceuticals is currently under evaluation in price to sales category among its peers.
Polydex Fundamentals
Return On Equity | -0.18 | |||
Return On Asset | -0.0824 | |||
Profit Margin | (0.25) % | |||
Operating Margin | (0.22) % | |||
Current Valuation | 2.23 M | |||
Shares Outstanding | 3.43 M | |||
Number Of Shares Shorted | 11 | |||
Price To Earning | 12.33 X | |||
Price To Book | 0.42 X | |||
Price To Sales | 0.51 X | |||
Revenue | 4.05 M | |||
Gross Profit | 970.3 K | |||
EBITDA | (568.16 K) | |||
Cash And Equivalents | 870.3 K | |||
Cash Per Share | 0.25 X | |||
Total Debt | 301.49 K | |||
Debt To Equity | 0.05 % | |||
Current Ratio | 5.88 X | |||
Book Value Per Share | 1.44 X | |||
Cash Flow From Operations | (238.54 K) | |||
Short Ratio | 0.02 X | |||
Earnings Per Share | (0.13) X | |||
Number Of Employees | 21 | |||
Beta | 0.33 | |||
Market Capitalization | 2.23 M | |||
Total Asset | 6.56 M | |||
Retained Earnings | (19.53 M) | |||
Working Capital | 2.12 M | |||
Current Asset | 3.41 M | |||
Current Liabilities | 1.28 M | |||
Z Score | 1.4 |
About Polydex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Polydex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Polydex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Polydex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
EBR | Centrais Electricas Brasileiras | |
HE | Hawaiian Electric Industries | |
VFC | VF Corporation | |
BVHMF | Vistry Group PLC | |
S | SentinelOne |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |